All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. Therefore there are no consolidated accounts for the Kancera Group produced...
Read MoreAll figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. Therefore there are no consolidated accounts for the Kancera Group produced...
Read MoreKancera together with international research groups in the project A-PARADDISE has been awarded a grant from the European Union Seventh Framework Programme to develop drugs to combat severe parasitic diseases including malaria, schistosomiasis, leishmaniasis and Chagas disease. The total...
Read MoreKancera reports progress in the development of a ROR-inhibiting cancer drug. The compound KAN0439365 is effective against cancer cells from patients and show good metabolic stability in human liver cells and blood. KAN0439365 is the first in a new...
Read MoreJanuary 1 - March 31, 2013 All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB. Therefore there are no consolidated accounts for the Kancera Group...
Read MoreAll figures relate to the Kancera Group unless otherwise specified. The 2011 comparison figures for operating income and income after financial items were affected by the release of negative goodwill of SEK 7m that arose in connection with the...
Read MoreAll figures relate to the Kancera Group unless otherwise specified. The 2011 comparison figures for operating income and income after financial items were affected by the release of negative goodwill of SEK 7m that arose in connection with the...
Read MoreKancera reports results from a collaboration with Professor Håkan Mellstedts research group at Karolinska Institute showing that the survival of an aggressive type of human cancer cells from pancreatic cancer is ROR-1 dependent. The results provide further support for...
Read MoreKancera reports that the company's first generation of PFKFB3 inhibiting compounds reduces growth of pancreatic cancer in a pre-clinical animal study.
Read MoreNEW YORK and STOCKHOLM, Oct. 04, 2012 - Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of proteinopathies, and iNovacia, a subsidiary to Kancera AB ...
Read More